Anti-IgE vaccines
AssigneePfizer Inc.
InventorsMohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
Claims10
A pharmaceutical composition comprising an immunogenically effective amount of one or more isolated antigenic fusion proteins consisting of the amino acid sequence of SEQ ID NO:
- 11 and a heterologous carrier protein, wherein said fusion protein induces a non-anaphylactic anti-IgE immune response when administered to an animal.
Dependencies are inferred from the claim text.